THC Farmaceuticals, Inc (OTC:CBDG) is pleased to announce the addition of Mark D. Grossman ESQ to its Board of Directors.
Mr. Grossman has been a licensed attorney since 1982. He brings extensive experience in all aspects of running a dental medical device manufacturing company including manufacturing, regulatory affairs, sales and management. He was responsible for the management of 4 manufacturing facilities and increased sales 600% between 1996 and 2009. In 2004 he was nominated for the Los Angeles Business Journals Second Generation Family Owned Business Award. He will be a valuable addition to our Board of Directors.
Bringing over a decade of research experience, Dr. Despanie completed his Pharmaceutical Sciences PhD at the University of Southern California following a BS in Biology from Louisiana State University.
Dr. Despanie began his biomedical career at LSU investigating molecular therapies such as oncolytic virotherapy and antiviral gene silencing before joining Johns Hopkins Hospital to probe how defective protein trafficking contributes to cystic fibrosis.
His dissertation, “Tubulin-based fusion proteins as multifunctional tools”, detailing a novel class of chemotherapy nanomedicines to combat triple-negative breast cancers (an aggressive disease subtype for which there are currently no targeted treatments) received over $178,000 in NIH grant funding.
In 2014, Dr. Despanie also founded S-aima Biopharmaceutics LLC, a biotech startup which sought to develop an artificial blood nanomedicine for temporary blood replacement on the battlefield and during civilian emergencies. An enthusiastic Dr. Despanie affirms, “This is a unique opportunity to leverage my passion for nanomedicine towards designing CBD formulations that will undoubtedly grant us a competitive edge in the marketplace.”
“We are thrilled and honored to have Dr. Jordan Despanie join CBDG. We look forward to working with him as we take CBDGs science to the next level, says Mike Gravel, Chairman and CEO of THC Farmaceuticals, Inc.